Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical Cystectomy


      To evaluate the impact of alvimopan in patient undergoing radical cystectomy (RC) for bladder cancer. We hypothesize that alvimopan can decrease cost for RC by reducing length of stay (LOS).


      We identified patients who underwent elective RC for bladder cancer from 2009 to 2015 in the Premier Healthcare Database, a nationwide, all-payer hospital-based database, and compared patients who received and did not receive alvimopan in the perioperative period. Hospitals that had no record of administering alvimopan for patients undergoing RC were excluded. The primary outcomes were LOS and the direct hospital costs. The secondary outcomes were 90-day readmission for ileus and major complications.


      After applying the inclusion criteria, the study cohort consisted of 1087 patients with 511 patients receiving perioperative alvimopan. Alvimopan was associated with a reduction in hospital costs by −$2709 (95% confidence interval: −$4507 to −$912, P = .003), decreased median LOS (7 vs 8 days, P < .001), and lower likelihood of readmission for ileus (adjusted odds ratio: 0.63, P = .041). While alvimopan use led to higher pharmacy costs, this was outweighed by lower room and board costs due to the reduced LOS. There was no significant difference between 2 groups regarding major complications. These results were robust across multiple adjusted regression models.


      Our data show that alvimopan is associated with a substantial cost-saving in patients undergoing RC, and suggest that routine use of alvimopan may be a potential cost-effective strategy to reduce the overall financial burden of bladder cancer.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Novara G
        • Catto JW
        • Wilson T
        • et al.
        Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy.
        Eur Urol. 2015; 67: 376-401
        • Svatek RS
        • Fisher MB
        • Matin SF
        • et al.
        Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria.
        J Urol. 2010; 183: 929-934
        • Cole AP
        • Ramaswamy A
        • Harmouch S
        • et al.
        Multilevel analysis of readmissions after radical cystectomy for bladder cancer in the USA: does the hospital make a difference?.
        Eur Urol Oncol. 2019; 2: 349-354
        • Raynor MC
        • Pruthi RS
        Postoperative ileus after radical cystectomy: looking for answers to an age-old problem.
        Eur Urol. 2014; 66: 273-274
        • Ramirez JA
        • McIntosh AG
        • Strehlow R
        • Lawrence VA
        • Parekh DJ
        • Svatek RS
        Definition, incidence, risk factors, and prevention of paralytic ileus following radical cystectomy: a systematic review.
        Eur Urol. 2013; 64: 588-597
        • Chang SS
        • Baumgartner RG
        • Wells N
        • Cookson MS
        • Smith Jr., JA
        Causes of increased hospital stay after radical cystectomy in a clinical pathway setting.
        J Urol. 2002; 167: 208-211
        • Leow JJ
        • Reese SW
        • Jiang W
        • et al.
        Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States.
        Eur Urol. 2014; 66: 569-576
        • Bansal SS
        • Dogra T
        • Smith PW
        • et al.
        Cost analysis of open radical cystectomy versus robot-assisted radical cystectomy.
        BJU Int. 2018; 121: 437-444
        • Wolff BG
        • Michelassi F
        • Gerkin TM
        • et al.
        Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus.
        Ann Surg. 2004; 240 (discussion 734-725): 728-734
        • Ludwig K
        • Enker WE
        • Delaney CP
        • et al.
        Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway.
        Arch Surg. 2008; 143: 1098-1105
        • Lee CT
        • Chang SS
        • Kamat AM
        • et al.
        Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial.
        Eur Urol. 2014; 66: 265-272
        • Manger JP
        • Nelson M
        • Blanchard S
        • Helo S
        • Conaway M
        • Krupski TL
        Alvimopan: a cost-effective tool to decrease cystectomy length of stay.
        Cent Eur J Urol. 2014; 67: 335-341
        • Hamilton Z
        • Parker W
        • Griffin J
        • et al.
        Alvimopan in an enhanced recovery program following radical cystectomy.
        Bladder Cancer (Amsterdam, Netherlands). 2015; 1: 137-142
        • Kauf TL
        • Svatek RS
        • Amiel G
        • et al.
        Alvimopan, a peripherally acting mu-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial.
        J Urol. 2014; 191: 1721-1727
        • Hilton WM
        • Lotan Y
        • Parekh DJ
        • Basler JW
        • Svatek RS
        Alvimopan for prevention of postoperative paralytic ileus in radical cystectomypatients: a cost-effectiveness analysis.
        BJU Int. 2013; 111: 1054-1060
        • Al-Mazrou AM
        • Baser O
        • Kiran RP
        Alvimopan, regardless of ileus risk, significantly impacts ileus, length of stay, and readmission after intestinal surgery.
        J Gastrointest Surg. 2018; 22: 2104-2116
        • Cole AP
        • Trinh QD
        Secondary data analysis: techniques for comparing interventions and their limitations.
        Curr Opin Urol. 2017; 27: 354-359
        • Tobis S
        • Heinlen JE
        • Ruel N
        • et al.
        Effect of alvimopan on return of bowel function after robot-assisted radical cystectomy.
        J Laparoendosc Adv Surg Tech A. 2014; 24: 693-697
        • Vora AA
        • Harbin A
        • Rayson R
        • et al.
        Alvimopan provides rapid gastrointestinal recovery without nasogastric tube decompression after radical cystectomy and urinary diversion.
        Can J Urol. 2012; 19: 6293-6298
        • Vora A
        • Marchalik D
        • Nissim H
        • et al.
        Multi-institutional outcomes and cost effectiveness of using alvimopan to lower gastrointestinal morbidity after cystectomy and urinary diversion.
        Can J Urol. 2014; 21: 7222-7227
        • Cui Y
        • Chen H
        • Qi L
        • Zu X
        • Li Y
        Effect of alvimopan on accelerates gastrointestinal recovery after radical cystectomy: a systematicreview and meta-analysis.
        Int J Surg (London, England). 2016; 25: 1-6
        • Sultan S
        • Coles B
        • Dahm P
        Alvimopan for recovery of bowel function after radical cystectomy.
        Cochrane Database Syst Rev. 2017; 5Cd012111
        • Kim SP
        • Shah ND
        • Weight CJ
        • et al.
        Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer.
        BJU Int. 2013; 112: 478-484
        • Gore JL
        • Yu HY
        • Setodji C
        • Hanley JM
        • Litwin MS
        • Saigal CS
        Urinary diversion and morbidity after radical cystectomy for bladder cancer.
        Cancer. 2010; 116: 331-339
        • Mossanen M
        • Krasnow RE
        • Lipsitz SR
        • et al.
        Associations of specific postoperative complications with costs after radical cystectomy.
        BJU Int. 2018; 121: 428-436
        • Leow JJ
        • Cole AP
        • Seisen T
        • et al.
        Variations in the costs of radicalcystectomy for bladder cancer in the USA.
        Eur Urol. 2018; 73: 374-382
        • Tyson MD
        • Chang SS
        Enhanced recovery pathways versus standard care after cystectomy: a meta-analysis of the effect on perioperative outcomes.
        Eur Urol. 2016; 70: 995-1003
        • Azhar RA
        • Bochner B
        • Catto J
        • et al.
        Enhanced recovery after urological surgery: a contemporary systematic review of outcomes, key elements, and research needs.
        Eur Urol. 2016; 70: 176-187
        • Nabhani J
        • Ahmadi H
        • Schuckman AK
        • et al.
        Cost analysis of the enhanced recovery after surgery protocol in patients undergoing radical cystectomy for bladder cancer.
        Eur Urol Focus. 2016; 2: 92-96
        • Leow JJ
        • Chang SL
        • Meyer CP
        • et al.
        Robot-assisted versus open radical prostatectomy: a contemporary analysis of an all-payer discharge database.
        Eur Urol. 2016; 70: 837-845
        • Jeong IG
        • Khandwala YS
        • Kim JH
        • et al.
        Association of robotic-assisted vs laparoscopic radical nephrectomy with perioperative outcomes and health care costs, 2003 to 2015.
        JAMA. 2017; 318: 1561-1568